default author photo

Rosine Guimbaud

University of Toulouse - Hospital Rangueil

SCHOLARLY PAPERS

3

DOWNLOADS

130

TOTAL CITATIONS

0

Scholarly Papers (3)

1.

Pemigatinib-associated toxicity and its management: implications on prognosis in patients with cholangiocarcinoma treated within real-world Italian PEMIREAL and French PEMIBIL cohorts

Number of pages: 20 Posted: 17 Dec 2025
affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Centre Hospitalier Universitaire de Toulouse, affiliation not provided to SSRN, Gustave Roussy - Drug Development Department (DITEP), University of Bordeaux - Hôpital Haut-Lévêque, affiliation not provided to SSRN, University of Montpellier - Institut régional du Cancer de Montpellier, Centre Paul Strauss, University of Claude Bernard Lyon 1 - Centre Léon Bérard, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Pisa, University of Perugia, affiliation not provided to SSRN, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Academic Hospital of Udine ASUFC - Department of Oncology, Université de Poitiers - Gastroenterology Department, affiliation not provided to SSRN, affiliation not provided to SSRN, Università Vita-Salute San Raffaele - IRCCS San Raffaele Scientific Institute, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Milano-Bicocca - Fondazione IRCCS San Gerardo dei Tintori, affiliation not provided to SSRN, affiliation not provided to SSRN, Centre Antoine Lacassagne, affiliation not provided to SSRN, University of Lille - CHU Lille, Institut de Cancérologie de l'Ouest - Department of Medical Oncology, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Institut Mutualiste Montsouris, École Normale Supérieure - PSL Research University - Institut Curie, Centre Eugène Marquis - Medical Oncology, Université de Rennes 1 - CHU de Rennes, University of Toulouse - Hospital Rangueil, IRCCS Humanitas Research Hospital, affiliation not provided to SSRN, Centre Hospitalier Universitaire de Toulouse and affiliation not provided to SSRN
Downloads 57 (1,041,696)

Abstract:

Loading...

Drug toxicity, adverse events, Cholangiocarcinoma, biliary tract cancer, FGFR2 fusions/rearrangements, Real-world Evidence, Systemic treatment, targeted therapy

2.

Prognostic Impact of the Braf V600e Mutation in Patients with Msi-High Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors

Number of pages: 29 Posted: 29 Apr 2025
affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori - Department of Medical Oncology, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - IRCCS Veneto Institute of Oncology (IOV-IRCCS), University of Toulouse - Hospital Rangueil, University of Toulouse - Hospital Rangueil, University of Texas at Houston - MD Anderson Cancer Center, Mayo Clinic, Université de Montpellier - Institut de Recherche en Cancérologie de Montpellier, University of Bordeaux - Hôpital Haut-Lévêque, affiliation not provided to SSRN, Vall d’Hebron Institute of Oncology (VHIO), University of Bordeaux - Institut Bergonié, University Hospital of Pisa - Unit of Medical Oncology, Gustave Roussy, University of Lille - CHU Lille, affiliation not provided to SSRN, CHU Rouen, CHU Poitiers, affiliation not provided to SSRN, City of Hope, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori - Department of Medical Oncology, Université Paris Cité and Université de Poitiers - Gastroenterology Department
Downloads 52 (1,074,648)

Abstract:

Loading...

Colorectal cancer, BRAF mutation, microsatellite instability, immune checkpoint inhibitor

3.

Braf + Egfr +/- Mek Inhibitors after Immune Checkpoint Inhibitors In Braf V600e Mutated and Deficient Mismatch Repair or Microsatellite Instability High Metastatic Colorectal Cancer

Number of pages: 23 Posted: 26 Jun 2024
Fondazione IRCCS Istituto Nazionale dei Tumori - Department of Medical Oncology, Université de Poitiers - Gastroenterology Department, Charité–Universitätsmedizin Berlin, University of Toulouse - Hospital Rangueil, University of Texas at Houston - MD Anderson Cancer Center, University of Bordeaux - Hôpital Haut-Lévêque, affiliation not provided to SSRN, Institut d’Hématologie et d’Oncologie Pédiatrique (iHOPe) - Centre Léon Bérard, affiliation not provided to SSRN, University of Toulouse - Hospital Rangueil, University of Pisa - Department of Translational Research and of New Surgical and Medical Technologies, University of Bordeaux - Institut Bergonié, Mayo Clinic, Vall d’Hebron Institute of Oncology (VHIO), University of Lille - CHU Lille, University Hospital of Pisa - Unit of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori - Department of Medical Oncology, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - IRCCS Veneto Institute of Oncology (IOV-IRCCS), affiliation not provided to SSRN and Université Paris Cité
Downloads 21 (1,448,301)

Abstract:

Loading...

Metastatic colorectal cancer, BRAF mutation, microsatellite instability high, deficient mismatch repair, immune checkpoint inhibitors, encorafenib, cetuximab